The Online Investor
Stock Buybacks
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Stock Buybacks

By The Online Investor Staff, updated Tue., Oct. 6, 12:20 PM

Slide #2. ANI Pharmaceuticals, Inc.

Company: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
$Amount Authorized: $25,000,000
Buyback Details: ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $25 million of shares of the Company's common stock. ANI expects to fund the stock repurchase program through cash on hand.

ANI Pharmaceuticals is a pharmaceutical company engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s targeted areas of product development include narcotics, oncolytics (anti-cancers), hormones and steroids, and formulations involving extended release and combination products. Co.'s products include, among others: Esterified Estrogen with Methyltestosterone, for the treatment of moderate to severe vasomotor symptoms of menopause; Fluvoxamine Maleate, for the treatment of patients with obsessive-compulsive disorder; and Hydrocortisone Enema and its equivalent, Cortenema for the treatment of ulcerative colitis.
Open the ANIP Page at The Online Investor »

Company Name:  ANI Pharmaceuticals, Inc.
Stock buyback:  ANIP buyback
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ANIP:  25
Total Market Value Held by ETFs:  $56.72M
Total Market Capitalization:  $499.00M
% of Market Cap. Held by ETFs:  11.37%

Open the ANIP Page at The Online Investor (in a new window) »

October 6, 2015    12:20 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
94th percentile
(ranked higher than approx. 94% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Buybacks | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.